Philips stock gains as Q3 margin expands and outlook holds

Philips reported stronger operating momentum in the third quarter on November 3, 2026, as comparable order intake rose 8% and comparable sales increased 3%. The company maintained its full-year outlook, while a Respironics-related provision continued to weigh on reported earnings.

Group sales reached EUR 4.4 billion, according to the Philips press release. Adjusted EBITA margin expanded 70 basis points to 13.0%, supported by higher sales, gross-margin gains and productivity measures. Operating cash flow was EUR 544 million and free cash flow reached EUR 384 million.

Orders support the growth plan

Demand was broad across the portfolio. Connected Care comparable sales increased 5%, while Personal Health grew 8%. Diagnosis & Treatment was broadly flat because growth in Image Guided Therapy was offset by lower Precision Diagnosis sales, including the previously cited phasing of ultrasound deliveries and weaker sales in China.

Philips said productivity initiatives generated EUR 170 million in net savings during the quarter and EUR 427 million year to date. Management remains on track for EUR 1.5 billion in savings under its 2026-2028 program. The company also highlighted continuing demand for AI-enabled imaging, image-guided therapy and monitoring solutions.

Respironics remains a key risk

Philips Respironics reached an agreement in principle with the US Department of Justice over previously disclosed criminal and civil investigations related to the recall. Philips recorded a EUR 288 million provision in the quarter, and payment is expected in the first quarter of 2027. Other ongoing Respironics proceedings, including an investigation by US state attorneys general, remain outside the outlook assumptions.

Philips stock traded at 27.49 euros on Lang & Schwarz at 11:30 CET on Thursday, November 12, 2026.

Outlook holds for 2026

Philips continues to target comparable sales growth of 3% to 4.5%, an adjusted EBITA margin of 13.5% to 14.0% and free cash flow of EUR 1.5 billion to EUR 1.7 billion. The free-cash-flow range includes an estimated net US tariff refund benefit of EUR 200 million, while the margin outlook includes a benefit of approximately 1% from the refund.

European healthcare stocks remain sensitive to hospital spending, tariffs and regulatory developments. Investors can follow the Euro Stoxx 50 for broader market context.

More news and analyses on Philips stock